Despite reporting lower revenues in the first half of the year, Formycon continues to see value in its biosimilar projects, with a new candidate to be launched in the second half of 2024.

Novel agents in immuno-oncology headline the drug center’s upcoming goal dates, while gene therapies make up most of the biologic center’s workload.

A third US biosimilar to Regeneron’s Eylea has won approval. However, enthusiasm is muted at this stage as biosimilar sponsors, including latest recipient Formycon, continue to battle against court-issued blockades.

Gain Therapeutics aims to offer a disease-modifying treatment for Parkinson’s patients with GCase mutations. The company’s promising data and platform face competition from notable rivals.